ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
100,766.61
-1.61%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Taysha Gene Therapies Inc (TSHA) 시세

Taysha Gene Therapies Inc

Taysha Gene Therapies Inc (TSHA)

NASDAQ
1.50
0.02
(1.35%)
마감 02 2월 6:00AM
15분 지연
1.49
-0.01
(-0.67%)
시간외 거래: 7:03AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
1.49
매수가
1.49
매도가
1.55
거래량
1,226,227
1.48 일간 변동폭 1.59
1.19 52주 범위 4.32
market_cap
305.366M
전일 종가
1.48
개장가
1.48
최근 거래 시간
1
@
1.51
마지막 거래 시간
재정 규모
US$ 1,865,466
VWAP
1.5213
평균 볼륨(3m)
4,315,742
발행 주식
204,943,306
배당수익률
-
주가수익률
-2.76
주당순이익(EPS)
-0.54
매출
15.45M
순이익
-111.57M

Taysha Gene Therapies Inc 정보

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and com... Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104. 더 보기

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
www.tayshagtx.com
본부
Dover, Delaware, USA
설립됨
-
Taysha Gene Therapies Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker TSHA. The last closing price for Taysha Gene Therapies was US$1.48. Over the last year, Taysha Gene Therapies shares have traded in a share price range of US$ 1.19 to US$ 4.32.

Taysha Gene Therapies currently has 204,943,306 shares in issue. The market capitalisation of Taysha Gene Therapies is US$303.32 million. Taysha Gene Therapies has a price to earnings ratio (PE ratio) of -2.76.

TSHA 최신 뉴스

추가 뉴스

Form S-8 - Securities to be offered to employees in employee benefit plans

08 1월 2025
Edgar (US Regulatory)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...

03 1월 2025
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

23 12월 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

14 12월 2024
Edgar (US Regulatory)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...

06 12월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 11월 2024
Edgar (US Regulatory)

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continued enrollment in cohort two...

14 11월 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

09 11월 2024
Edgar (US Regulatory)

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13

DALLAS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene...

06 11월 2024
GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus...

02 11월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.02-1.324503311261.511.591.4424359581.50953873CS
4-0.4-21.1640211641.892.071.4422557111.66240627CS
120.074.929577464791.423.311.443157422.20865557CS
26-0.77-34.07079646022.263.311.1929968552.0814857CS
52-0.01-0.6666666666671.54.321.1928665752.37735839CS
156-5.95-79.97311827967.448.92990.519313842.34860316CS
260-20.76-93.303370786522.2533.840.513718382.94852141CS

TSHA - Frequently Asked Questions (FAQ)

What is the current Taysha Gene Therapies share price?
The current share price of Taysha Gene Therapies is US$ 1.49
How many Taysha Gene Therapies shares are in issue?
Taysha Gene Therapies has 204,943,306 shares in issue
What is the market cap of Taysha Gene Therapies?
The market capitalisation of Taysha Gene Therapies is USD 303.32M
What is the 1 year trading range for Taysha Gene Therapies share price?
Taysha Gene Therapies has traded in the range of US$ 1.19 to US$ 4.32 during the past year
What is the PE ratio of Taysha Gene Therapies?
The price to earnings ratio of Taysha Gene Therapies is -2.76
What is the cash to sales ratio of Taysha Gene Therapies?
The cash to sales ratio of Taysha Gene Therapies is 19.89
What is the reporting currency for Taysha Gene Therapies?
Taysha Gene Therapies reports financial results in USD
What is the latest annual turnover for Taysha Gene Therapies?
The latest annual turnover of Taysha Gene Therapies is USD 15.45M
What is the latest annual profit for Taysha Gene Therapies?
The latest annual profit of Taysha Gene Therapies is USD -111.57M
What is the registered address of Taysha Gene Therapies?
The registered address for Taysha Gene Therapies is 108 LAKELAND AVE, DOVER, DELAWARE, 19901
What is the Taysha Gene Therapies website address?
The website address for Taysha Gene Therapies is www.tayshagtx.com
Which industry sector does Taysha Gene Therapies operate in?
Taysha Gene Therapies operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.82M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.39M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.58M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.91M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.93k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
900.48k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.42M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
234.8M

TSHA Discussion

게시물 보기
georgie18 georgie18 1 주 전
TSHA...$1.53... 🥳... https://finviz.com/insidertrading.ashx?oc=1494695&tc=7 ...Bullish Harami Cross Reversal Pattern...
👍️0
glenn1919 glenn1919 1 월 전
tsha..........................https://stockcharts.com/h-sc/ui?s=tsha&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 월 전
TSHA, under $2

👍️0
glenn1919 glenn1919 2 월 전
TSHA.....................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 월 전
TSHA..............https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 월 전
TSHA...$2.58...Off the $2.10 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 85

Tuesday, November 12, 2024 3:56:56 PM

Post#
89
of 90
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
glenn1919 glenn1919 3 월 전
TSHA............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 월 전
TSHA...$2.41...🥳...on the $2.10 gapper alert...All out for now...will revisit...

georgie18

Member Level
Re: None

Monday, November 11, 2024 5:18:23 PM

Post#
664504
of 664675
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
zendeli1 zendeli1 3 월 전
restart soon
👍️0
glenn1919 glenn1919 3 월 전
TSHA....................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 월 전
TSHA.................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 3 월 전
TSHA...$2.10... https://schrts.co/KsMDABsM ...Psar flipped Bullish...🥳Should be a gapper in the morning...
👍️0
nsomniyak nsomniyak 3 월 전
I sent an email to TSHA IR on 11/5 asking if they could explain the sharp drop (at that time) and high volume in the stock. I did not receive an answer.
👍️0
nsomniyak nsomniyak 3 월 전
Premiums were high all last week and today on TSHA call options. Volume in the common has been high as well.
👍️0
Pip611 Pip611 3 월 전
I was thinking the same thing, it started to pop in the afternoon and now it took off after hours
👍️0
nsomniyak nsomniyak 3 월 전
What is going on with TSHA in the AH today? Up sharply - now 2.10
👍️0
Monksdream Monksdream 3 월 전
TSHA under $3
👍️0
Monksdream Monksdream 6 월 전
TSHA under $3
👍️0
TechandBio TechandBio 7 월 전
Started buying shares last year at .77 Riding the houses money now and sold three quarters of my shares at $4.00 range when I saw the double top formation come into play I can see this going to $8.00-$10.00 only on a buyout in the next year. Risky with only a handful of patients dosed and the competition for Rhett but a cunning bet with the management at TSHA. now.
CEO and CMO are best in class. Not a core position but glad I'm in with a few. I hope they have a remedy for these poor kids with Rhett.

$TSHA
👍️0
nsomniyak nsomniyak 7 월 전
If these are senior people in prominent management or technical roles it is pretty standard for them to be granted options as part of their compensation package. They vest over 4 years, so it is not an outright giveaway.

Additionally, since these are NEW employees, by definition they have not manipulated the stock down to get a lower option strike price.

I am fine with this very normal comp package.
👍️ 1
ErnieBilco ErnieBilco 7 월 전
I'm sorry but granting options to NEW employees is absurd - they shouldn't be entitled to stock options UNTIL their one year on the job.

No wonder why this has trouble making gains for shareholders whom the employees actually work for.
👍️0
LegendaryNomad22 LegendaryNomad22 7 월 전
Weird. Both TSHA and NGNE have gene therapy candidates for Rett and both of them tanked today, despite sharing strong interim results. There's an International Rett Syndrome Foundation meeting today and tomorrow, so I wonder if something happened there to take the wind out of the gene therapy treatment class. Anyone have any knowledge here?
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
Diluted on news
👍️0
Pip611 Pip611 8 월 전
Ouch - what happen?
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA...GAPPING
👍️0
Tiger Money Tiger Money 8 월 전
Yes, no sorry, didn’t mean to imply that. I was asking if you have other bio names you have on your radar (obviously know about this and Huma). Thanks
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
chart has nothing to do with what sector!!
👍️0
Tiger Money Tiger Money 8 월 전
You have the bios nailed down! Any I should put on my radar? As always, thank you as I sincerely appreciate your help and knowledge. Thanks!
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA BREAK OUT
👍️0
Monksdream Monksdream 8 월 전
TSHA new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA...HERES 4 DOLLA
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA...READY FOR 4
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA...BIO BEAST BREAKING HEWRE CHAINS
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA HERE WE GO ON THE BREAK OUT!!
👍️0
glenn1919 glenn1919 8 월 전
TSHA......................................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA HERE COMES THE BREAK
👍️0
TrendTrade2016 TrendTrade2016 8 월 전
TSHA...NEXT BIO READY TO BEAST!
👍️0
FooBarAndGrill FooBarAndGrill 8 월 전
Taysha may have the real ONE-SHOT genetic cure. It may REALLY work.
Good luck getting any health insurance plan to list this $Million dollar shot in their drug formulary.
👍️0
Monksdream Monksdream 8 월 전
TSHA under $5
👍️0
glenn1919 glenn1919 10 월 전
TSHA..............................https://stockcharts.com/h-sc/ui?s=TSHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
TSHA..READY TO PUSH TO 4.00
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 10 월 전
TSHA...HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 11 월 전
TSHA..here we go
👍️0
TrendTrade2016 TrendTrade2016 11 월 전
TSHA...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 11 월 전
TSHA NEXT BIO BEAST TO RUN TO 3.61 WATCH THE MAGIC
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
“Dosing the first pediatric patient with Rett syndrome marks an important step forward in our efforts to broaden the clinical evaluation of TSHA-102 to younger patients with earlier stages of Rett syndrome. We are pleased with our progress on expanding the study of TSHA-102 across a broad population of ages and stages of Rett syndrome to bring a potentially transformative treatment option to all patients and families suffering from this devastating disease,” said Sukumar Nagendran, M.D., President, and Head of R&D of Taysha. “The pediatric trial will build on our ongoing REVEAL adolescent and adult trial, where early data demonstrated improvements across multiple clinical domains in adult patients with the most advanced stage of disease. We also plan to expand our U.S. pediatric trial into the U.K. following the recent acceptance of our CTA by the MHRA.”
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
Estimated Enrollment : 18 participants
(was 12).
https://classic.clinicaltrials.gov/ct2/show/NCT05606614
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
“Following review of the initial clinical data from the first two adult patients treated with TSHA-102 and Chemistry, Manufacturing, and Controls (CMC) data, Health Canada has authorized our protocol amendment to include adolescent patients aged 12 years and older in the ongoing REVEAL Phase 1/2 adult trial,”
https://ih.advfn.com/stock-market/NASDAQ/taysha-gene-therapies-TSHA/stock-news/92678004/taysha-gene-therapies-announces-expanded-eligibili
👍️0
FooBarAndGrill FooBarAndGrill 1 년 전
The P1 TSHA-102 REVEAL Adult Study has been on a slow boat.
Hopefully, the Clinical Updates PR will give the push to finally complete enrollment of the 12 adult female Rett patients needed for the trial.
I'm guessing reluctance to enroll has been based on the one-time injection into the intrathecal space (directly into the Cerebral Spinal Fluid).
It's definitely worth the risk, IMO. Good Luck to All.
👍️0

최근 히스토리

NASDAQ
TSHA
Taysha Gene Therapies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지